HomeVasa Therapeutics announces positive topline results from randomised, placebo-controlled phase 1c trial...

Vasa Therapeutics announces positive topline results from randomised, placebo-controlled phase 1c trial of VS-041 for treatment of heart failure with preserved ejection fraction (HFpEF)

Vasa Therapeutics has announced positive results from a randomised, placebo-controlled phase 1c trial of its lead investigational therapy, VS-041, a narrow spectrum small molecule inhibitor of matrix metalloproteinases (MMPs) for the treatment of heart failure with preserved ejection fraction (HFpEF) demonstrating a clinical proof-of-concept in the affected population.

VS-041 achieved a reduction in NT-proBNP, an important biomarker of cardiac wall stress and heart failure in patients receiving background guideline-directed medical therapy for HFpEF.

At two doses of treatment, VS-041 was safe and well-tolerated.

The study also supported the utility of using serum endotrophin, as measured by the NordicProC6 assay, to identify a more homogenous subpopulation of patients with fibroinflammation as the likely cause of diastolic dysfunction.

Ongoing analyses of exploratory clinical measures and markers of fibroinflammation and collagen turnover in the extracellular matrix (ECM) will be presented in early 2027. 

VS-041 was demonstrated to ameliorate cardiac fibrosis and improve diastolic function in preclinical models of HFpEF.

In healthy participant phase 1 clinical trial, VS-041 was safe and well-tolerated at doses commensurate with preclinical efficacy.

VS-041 was awarded fast track designation by the Food and Drug Administration in November 2025. 

- Advertisment -
- Advertisment -

Most Popular

Popular categories